European Journal of Clinical Pharmacology

, Volume 68, Issue 11, pp 1517–1524

Population pharmacokinetics and Bayesian estimation of cyclosporine in a Tunisian population of hematopoietic stem cell transplant recipient

Authors

    • Laboratoire de Pharmacologie CliniqueCentre National de Pharmacovigilance
  • Emna Gaies
    • Laboratoire de Pharmacologie CliniqueCentre National de Pharmacovigilance
    • Faculté de Médecine
  • Nadia Ben Fradj
    • Laboratoire de Pharmacologie CliniqueCentre National de Pharmacovigilance
    • Faculté de Médecine
  • Nadia Jebabli
    • Laboratoire de Pharmacologie CliniqueCentre National de Pharmacovigilance
    • Faculté de Médecine
  • Issam Salouage
    • Laboratoire de Pharmacologie CliniqueCentre National de Pharmacovigilance
    • Faculté de Médecine
  • Sameh Trabelsi
    • Laboratoire de Pharmacologie CliniqueCentre National de Pharmacovigilance
    • Faculté de Médecine
  • Mohamed Lakhal
    • Laboratoire de Pharmacologie CliniqueCentre National de Pharmacovigilance
    • Faculté de Médecine
  • Anis Klouz
    • Laboratoire de Pharmacologie CliniqueCentre National de Pharmacovigilance
    • Faculté de Médecine
Pharmacokinetics and Disposition

DOI: 10.1007/s00228-012-1275-9

Cite this article as:
Eljebari, H., Gaies, E., Fradj, N.B. et al. Eur J Clin Pharmacol (2012) 68: 1517. doi:10.1007/s00228-012-1275-9

Abstract

Purpose

Therapeutic drug monitoring of cyclosporine minimizes the risk of toxicity and acute rejection after transplantation. Areas under the curve (AUCs) rather than trough concentration-based monitoring are recommended. Population pharmacokinetics (PopPK) modeling and Bayesian estimation seem to be the best way to predict cyclosporine disposition and dose requirements to achieve the therapeutic target in an individual patient because of the possibility of predicting cyclosporine AUC using only a few blood samples. Our objectives were to build a PopPk model for cyclosporine in a Tunisian population of HSCT patients and to develop a Bayesian method for the estimation of individual cyclosporine AUC.

Patients and methods

The PopPk of cyclosporine was studied using nonlinear mixed effects modeling (NONMEM) in 30 patients (index group) receiving cyclosporine on a twice-daily basis. Ten blood samples were collected after steady-state morning cyclosporine dose. Bayesian estimation of individual AUC was made on the basis of three blood concentration measurements in an independent group of 30 patients (test group).

Results

A two-compartment model with first-order absorption and a lag time provided the best fitting. The population mean estimate and interindividual variability from the final model for CL, Ka, Tlag, V1, V2, and Q were 25.4 L/h (CV = 38.72 %), 0.214 h−1(CV = 28.5 %), 0.382 h, 10.9 L (85.73 %), 496 L, and 5 L/h, respectively. Covariates had no discernible effects on cyclosporine pharmacokinetics in our population. Bayesian estimation provided an accurate estimation of AUC, although a bias was observed leading to slight underprediction of AUC (bias −1.03 %). A very satisfactory precision was observed (RMSE 12.07 %).

Conclusion

We report a PopPK model for cyclosporine in Tunisian HSCT patients. Bayesian estimation using only three concentrations provides good prediction of cyclosporine exposure. These tools allow us to routinely estimate cyclosporine AUC in a clinical setting.

Keywords

CyclosporinePopulation pharmacokineticsHematopoietic stem cell transplantationNONMEMBayesian estimation

Copyright information

© Springer-Verlag 2012